Open Access

TRIM31 enhances chemoresistance in glioblastoma through activation of the PI3K/Akt signaling pathway

  • Authors:
    • Ming‑De Fan
    • Xue‑Ying Zhao
    • Jian‑Ni Qi
    • Yang Jiang
    • Bing‑Yu Liu
    • Zhi‑Ping Dun
    • Rui Zhang
    • Cheng‑Wei Wang
    • Qi Pang
  • View Affiliations

  • Published online on: May 21, 2020     https://doi.org/10.3892/etm.2020.8782
  • Pages: 802-809
  • Copyright: © Fan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Temozolomide (TMZ) resistance is a complication of treatment of glioma, and new strategies are urgently required to overcome chemoresistance in glioma cells. In the present study, it was demonstrated that tripartite motif‑containing 31 (TRIM31) was abnormally upregulated in glioma tissues and cell lines compared with normal samples. Furthermore, the role of TRIM31 was assessed by overexpressing and knocking down its expression. Overexpression of TRIM31 increased cell viability, increased TMZ IC50 values and inhibited apoptosis in A172 and U251 cells; whereas overexpression of TRIM31 decreased the expression of the apoptosis‑associated protein p53. Knockdown of TRIM31 increased apoptosis in cells treated with TMZ. Additionally, the mechanisms by which TRIM31 affected glioma cells treated with TMZ were determined. Overexpression of TRIM31 increased phosphorylation of AKT and inhibiting the PI3K/AKT signaling pathway abolished the increase in cell viability and decreased phospho‑Akt protein expression in TRIM31 overexpressing A172 cells treated with TMZ. Together, the findings suggest that TRIM31 may be a potentially novel target for glioma chemotherapy.
View Figures
View References

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fan MD, Zhao XY, Qi JN, Jiang Y, Liu BY, Dun ZP, Zhang R, Wang CW and Pang Q: TRIM31 enhances chemoresistance in glioblastoma through activation of the PI3K/Akt signaling pathway. Exp Ther Med 20: 802-809, 2020
APA
Fan, M., Zhao, X., Qi, J., Jiang, Y., Liu, B., Dun, Z. ... Pang, Q. (2020). TRIM31 enhances chemoresistance in glioblastoma through activation of the PI3K/Akt signaling pathway. Experimental and Therapeutic Medicine, 20, 802-809. https://doi.org/10.3892/etm.2020.8782
MLA
Fan, M., Zhao, X., Qi, J., Jiang, Y., Liu, B., Dun, Z., Zhang, R., Wang, C., Pang, Q."TRIM31 enhances chemoresistance in glioblastoma through activation of the PI3K/Akt signaling pathway". Experimental and Therapeutic Medicine 20.2 (2020): 802-809.
Chicago
Fan, M., Zhao, X., Qi, J., Jiang, Y., Liu, B., Dun, Z., Zhang, R., Wang, C., Pang, Q."TRIM31 enhances chemoresistance in glioblastoma through activation of the PI3K/Akt signaling pathway". Experimental and Therapeutic Medicine 20, no. 2 (2020): 802-809. https://doi.org/10.3892/etm.2020.8782